Drug Profile
Research programme: induced pluripotent stem cell therapies - Opsis Therapeutics
Latest Information Update: 23 May 2021
Price :
$50
*
At a glance
- Originator Opsis Therapeutics
- Class Eye disorder therapies; Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Dry age-related macular degeneration; Retinal disorders
Most Recent Events
- 23 May 2021 Preclinical trials in Retinal disorders in USA (Parenteral)
- 17 May 2021 BlueRock Therapeutics, FUJIFILM Cellular Dynamics, and Opsis Therapeutics enters into R&D agreement for the development of T cell immunotherapies
- 17 May 2021 Preclinical trials in Dry age-related macular degeneration in USA (Parenteral)